My top FTSE 100 buys for a 2019 starter portfolio

These 10 FTSE 100 (INDEXFTSE:UKX) industry giants haven’t been this cheap for over five years.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Every quarter I take a look at the biggest FTSE 100 companies in each of the index’s 10 industries to see how they shape up as a potential starter portfolio. At the start of 2019, the average earnings rating of this group of companies is cheaper than it’s been for over five years.

The table below shows their individual valuations based on forecast 12-month price-to-earnings (P/E) ratios and dividend yields.

Company Industry Share price (p) P/E Yield (%)
BAE Systems Industrials 465 10.3 5.0
British American Tobacco (LSE: BATS) Consumer Goods 2,479 7.9 8.5
GlaxoSmithKline Health Care 1,500 13.2 5.3
HSBC Financials 647 10.9 6.2
National Grid Utilities 774 13.3 6.3
Rio Tinto Basic Materials 3,690 10.6 5.9
Royal Dutch Shell Oil & Gas 2,363 9.7 6.2
Sage Technology 599 19.1 2.9
Tesco Consumer Services 192 11.8 3.6
Vodafone Telecommunications 155 15.9 8.7

The average P/E of the group is 12.3 and the average dividend yield is 5.9%. To put this into historical context, the table below shows average P/Es and yields for the last four quarters and six years.

  P/E Yield (%)
January 2019 12.3 5.9
October 2018 13.3 5.3
July 2018 14.7 4.8
April 2018 14.2 5.0
January 2018 16.3 4.5
January 2017 17.0 4.4
January 2016 13.7 6.0
January 2015 13.5 4.8
January 2014 12.7 4.5
January 2013 11.7 4.6

Looking at my records, I have to go back to the October 2013 quarter to find the group average P/E as cheap as it is today. Furthermore, at 12.3, it’s firmly in my ‘good value’ band. My rule of thumb is that an average P/E below 10 is bargain territory, 10 to 14 is good value, and above 14 starts to move towards expensive.

Markets could continue to be volatile for the foreseeable future, but I see this as a terrific opportunity to snap up some core blue-chip stocks for a starter portfolio. Indeed, with the exception of technology firm Sage, I’d happily buy these Footsie heavyweights today.

Personally, I have Sage marked as a stock to avoid for now, because I believe the high P/E represents poor value for the company’s downgraded and uncertain earnings outlook. However, a number of my colleagues are keen on the stock — some rating it a top buy for 2019 — so you may want to look into the bull case.

Wide margin of safety

Sage aside, I see so much value on offer across the board that it’s hard to highlight any one of the nine stocks for special attention. British American Tobacco (BAT) is perhaps the most eye-catching, having the lowest P/E by some margin at 7.9 and with the second-highest dividend yield at 8.5%.

Tobacco stocks in general have fallen out of favour over the last year or two, but BAT has been hit particularly hard by adverse investor sentiment. It’s suffered not only from sector-wide concerns about regulation, but also from its much higher exposure than its peers to the US menthol cigarettes market. Regulators there are looking at banning menthol cigarettes. Another concern about the company is its current relatively high level of debt, following its $49bn acquisition of Reynolds American.

With investors shying away from the sector and the firm having company-specific issues to boot, its shares have fallen considerably further than those of its rivals. They’re currently 56% down from their all-time high of 5,643p in the summer of 2017. But I think the market’s being far too pessimistic about the company’s future.

The menthol cigarettes ban in the US is unlikely to happen for years, if ever, while the company’s debt-reduction plans look perfectly plausible to me. Moreover, with its share price having been hammered down to the extent it has, it offers a wide margin of safety against any future earnings setback.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended HSBC Holdings, Sage Group, and Tesco. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »